The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...